DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
CP1-1189 is an investigational drug.
There have been 4 clinical trials for CP1-1189. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2009.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, and Leukemia, Myelogenous, Chronic, BCR-ABL Positive. The leading clinical trial sponsors are EA Pharma Co., Ltd., National Cancer Institute (NCI), and H. Lee Moffitt Cancer Center and Research Institute.
Recent Clinical Trials for CP1-1189
|A Single Intravenous Dose Study of E3112 in Japanese Healthy Adult Male Subjects||EA Pharma Co., Ltd.||Early Phase 1|
|Nilotinib Pre and Post Allogeneic Stem Cell Transplantation||Sheba Medical Center||Phase 2|
|Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004)||University of Leipzig||Phase 1/Phase 2|